Literature DB >> 22750230

Mechanism of inhibition of lipopolysaccharide-induced interferon-β production by 2-aminopurine.

Tsuyoshi Sugiyama1, Takaki Gotou, Kazuya Moriyama, Nodoka Kajiura, Takuya Hasegawa, Junko Tomida, Keita Takahashi, Takayuki Komatsu, Hiroshi Ueda, Katsuya Sato, Shunji Tokoro, Paola Neri, Hiroshi Mori.   

Abstract

2-Aminopurine (2-AP) is widely used as an inhibitor for double stranded RNA-dependent protein kinase (PKR). Previously, we reported that 2-AP inhibits Toll-like receptor (TLR) ligand-induced nitric oxide production through the prevention of interferon (IFN)-β production. In this study, we investigated the mechanisms for 2-AP inhibition of lipopolysaccharide (LPS)-induced IFN-β production. A reporter gene assay showed that LPS-induced IFN-β promoter, but not nuclear factor (NF)-κB, activation was significantly inhibited by 2-AP. IFN-β promoter activation induced by the overexpression of Toll/interleukin-1 receptor domain-containing adaptor inducing IFN-β (TRIF) was significantly inhibited by 2-AP in a dose-dependent manner, while TRIF- or myeloid differentiation primary response gene 88-dependent NF-κB activation was not inhibited. IFN-β promoter activation induced by expression of the downstream signaling molecules, tumor necrosis factor receptor-associated factor family member-associated NF-κB activator-binding kinase 1, inhibitor of NF-κB kinase i and a constitutively active mutant of interferon regulatory factor (IRF)-3, was also inhibited by 2-AP. Another PKR inhibitor harboring the imidazolo-oxindole structure, however, did not affect TRIF signaling molecules-induced IFN-β promoter activation, suggesting that the inhibition of IFN-β transcription by 2-AP is independent of PKR inhibition. Further, we examined the effect of 2-AP on LPS-induced IRF-3 activation by immunoblotting. While 2-AP did not affect LPS-induced phosphorylation of IRF-3, nuclear translocation of IRF-3 was inhibited. Moreover, we revealed that LPS-induced phosphorylation of Akt, another key molecule involved in IRF-3 activation, was inhibited by 2-AP. These results suggest that 2-AP inhibits nuclear translocation of phosphorylated-IRF-3 by inhibiting Akt activation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750230     DOI: 10.1016/j.molimm.2012.06.008

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Inhibitory mechanism of 10-hydroxy-trans-2-decenoic acid (royal jelly acid) against lipopolysaccharide- and interferon-β-induced nitric oxide production.

Authors:  Tsuyoshi Sugiyama; Keita Takahashi; Akihiro Kuzumaki; Shunji Tokoro; Paola Neri; Hiroshi Mori
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

2.  The sst1 resistance locus regulates evasion of type I interferon signaling by Chlamydia pneumoniae as a disease tolerance mechanism.

Authors:  Xianbao He; Robert Berland; Samrawit Mekasha; Thomas G Christensen; Joseph Alroy; Igor Kramnik; Robin R Ingalls
Journal:  PLoS Pathog       Date:  2013-08-29       Impact factor: 6.823

3.  2-aminopurine suppresses the TGF-β1-induced epithelial-mesenchymal transition and attenuates bleomycin-induced pulmonary fibrosis.

Authors:  Dong Weng; Jian-Xia Chen; Hao-Hao Li; Feng Liu; Li-Dan Zhou; Hai-Peng Liu; Rui-Juan Zheng; Yan Jiang; Zhong-Hua Liu; Baoxue Ge
Journal:  Cell Death Discov       Date:  2018-02-13

4.  Characterization and Transcript Expression Analyses of Atlantic Cod Viperin.

Authors:  Khalil Eslamloo; Atefeh Ghorbani; Xi Xue; Sabrina M Inkpen; Mani Larijani; Matthew L Rise
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

5.  Vaccinia Virus Protein B18R: Influence on mRNA Immunogenicity and Translation upon Non-Viral Delivery in Different Ocular Cell Types.

Authors:  An-Katrien Minnaert; Joke Devoldere; Karen Peynshaert; Laure Vercruysse; Stefaan C De Smedt; Katrien Remaut
Journal:  Pharmaceutics       Date:  2021-01-07       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.